- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05117372
ANALYSIS OF INFLAMMATORY REACTIONS OBSERVED IN BRONCHOALVEOLAR LAVAGES (BALS) (LBA-PI)
ANALYSIS OF INFLAMMATORY REACTIONS OBSERVED IN BRONCHOALVEOLAR LAVAGES (BALS) PERFORMED FOR INFILTRATIVE LUNG DISEASE THAT COMPLICATE ANTI PD-(L)1 IMMUNOTHERAPIES
Immunological toxicities associated with immune checkpoint inhibitor (ICI) monoclonal antibodies are unpredictable autoimmune and inflammatory pathologies that can affect all treated patients. Some of these events are severe and occur in 15-20% of patients treated with Programmed Death 1 (PD-1) antibodies.
The study of cellular immunological characteristics within tissues affected by toxicities and the interactions between the different actors of these toxicities aims at improving the knowledge concerning the mechanisms of these toxicities, but also at being able to specify the unexpected effects of ICIs on cells of the immune system, outside the tumor microenvironment.
Diffuse infiltrative lung disease is one of the most frequent and severe toxicities encountered in patients treated with anti PD-(L)1; either for bronchial cancer, melanoma or any other type of cancer. Patients developing this type of complication benefit from cytological, bacteriological, mycological and molecular analyses of intra-alveolar constituents obtained by bronchoalveolar lavage (BAL) performed during bronchial fibroscopy as part of their routine care. These analyses help to confirm the diagnosis of alveolitis, to specify the cellular characteristics of alveolar inflammation and to eliminate differential diagnoses of ICI toxicity.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Jérôme LE PAVEC, MD
- Telefonnummer: 01.40.94.24.30
- E-post: J.lepavec@ghpsj.fr
Studieorter
-
-
-
Le Plessis Robinson, Frankrike, 92350
- Rekrytering
- Centre Chirurgical Marie Lannelongue
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adult subject (≥ 18 years old)
- Patient having consented to the research
Group 1:
- Patient with cancer who was treated with immunotherapy
- Appearance of CT lung abnormalities during immunotherapy, not related to cancer
- With high suspicion of infiltrative lung disease:
- Pneumopathy (CTCAE version 5 classification).
- Patients requiring bronchial fibroscopy with BAL
Groups 2:
- Patient with lung cancer with peripheral tumor
- Requires surgical pulmonary lobectomy in the operating room
Exclusion Criteria:
- Patient treated or having been treated in the last 2 months with corticosteroid therapy
- Patient treated with immunosuppressant and/or cyclophosphamide, and/or Anti-TNF α in the last 12 months
- Absence of consent
- Patient under curatorship, guardianship or safeguard of justice
- Pregnant woman
- Group 1:
- Patient with respiratory failure
Groups 2:
- Patient with lung cancer with proximal or endobronchial tumor
- Patients requiring bilobectomy or pneumonectomy
- Patient who has been treated with immunotherapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
Group 1: Patients treated for cancer with immunotherapy and developing diffuse infiltrative lung disease
|
Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
|
Placebo-jämförare: Patients not treated with immunotherapy and requiring carcinologic lobectomy
Group 2: Patients with lung cancer not treated with immunotherapy and requiring carcinologic lobectomy
|
Patients requiring carcinologic lobectomy
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Expression levels of cellular and soluble actors involved in the occurrence of pulmonary toxicities associated with antitumor immunotherapies
Tidsram: 1 day
|
1 day
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2020-A01626-33
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Lungcancer
-
Chang Gung Memorial HospitalAvslutad
-
University of ZurichDeep Breath Intelligence (DBI)RekryteringLung-/luftvägssjukdomarSchweiz
-
424 General Military HospitalAvslutad
-
Celularity IncorporatedAvslutadSteg 2 Lung sarkoidos | Steg 3 Lung sarkoidosFörenta staterna
-
Centre Hospitalier Universitaire, AmiensAvslutadHemodialyskomplikation | Lung ultraljudFrankrike
-
Tuberculosis Research Centre, IndiaInternational Union Against Tuberculosis and Lung Diseases; Sarvodaya Charitable... och andra samarbetspartnersAktiv, inte rekryterandePre-extensivt läkemedelsresistent lung-TB | Behandling Intolerant multiresistent lung-TB | Icke-responsiv multiresistent lung-TBIndien
-
Papa Giovanni XXIII HospitalAvslutadLungtransplantation | Ex Vivo Lung PerfusionItalien
-
Pontificia Universidad Catolica de ChileRekryteringLung ultraljud | Öppen bukkirurgiChile
-
University of Colorado, DenverChildren's Hospital Colorado; Food and Drug Administration (FDA)AvslutadHypertoni;Lung;PrimärFörenta staterna
-
University Hospital, LilleAvslutad